Trinity Biotech (NASDAQ:TRIB) Stock Passes Above Two Hundred Day Moving Average of $2.13

Trinity Biotech plc (NASDAQ:TRIBGet Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.13 and traded as high as $2.39. Trinity Biotech shares last traded at $2.28, with a volume of 76,514 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Trinity Biotech in a report on Monday, June 3rd. They issued a “buy” rating on the stock.

Get Our Latest Research Report on Trinity Biotech

Trinity Biotech Price Performance

The stock has a market cap of $17.38 million, a P/E ratio of -0.82 and a beta of 1.16. The stock has a 50-day simple moving average of $1.79 and a 200-day simple moving average of $2.13.

Trinity Biotech (NASDAQ:TRIBGet Free Report) last released its quarterly earnings data on Thursday, April 4th. The company reported ($0.68) earnings per share (EPS) for the quarter. The company had revenue of $13.43 million for the quarter. As a group, sell-side analysts forecast that Trinity Biotech plc will post -2.17 earnings per share for the current year.

About Trinity Biotech

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Featured Articles

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.